New class
- Entire new class of small molecule antibiotics
- New mechanism of action independent to present resistance mechanisms of MDR bacteria
High potency
- Bactericidal against both Gram-positive and Gram-negative MDR bacteria
- Effective against e.g. ESKAPE pathogens
Single or combined use
- Effective as monotherapy
- Strong synergistic interaction with common antibiotics by reversing microbial resistance at sub-MIC levels
Safety
- Promising safety and tolerability profile with no observed adverse effect level (NOAEL)
- No CNS effect
- Excellent PK/PD properties in preclinical tests
Simple
- Easy to manufacture small molecules
- Stable compounds
- Low cost of production
IV/oral switch
- High bioavailability
- Suitable for IV/oral switch therapy
- Multiple potential routes of administration
Excellent Market Potential
- Addresses significant unmet clinical need
- Large, growing market for antibiotics against MDR infections
- Strong platform for future development
Strong IP
- Comprehensive patent portfolio (2025-2035 ++)
- Full freedom to operate
Qualifies for GAIN
- Eligible for priority review and fast track approval
- Extension of market exclusivity